GLP-1 derivative liraglutide in rats with β-cell deficiencies: Influence of metabolic state on β-cell mass dynamics

British Journal of Pharmacology

Volumn 140, Issue 1, 2003, Pages 123-132

  Sturis, Jeppe ^a   Gotfredsen, Carsten F ^a   Rømer, John ^a   Rolin, Bidda ^a   Ribel, Ulla ^a   Brand, Christian L ^a   Wilken, Michael ^a   Wassermann, Karsten ^a   Deacon, Carolyn F ^b   Carr, Richard D ^a   Knudsen, Lotte Bjerre ^a  

^a NOVO NORDISK A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

60 pancreatectomy; Glucagon like peptide 1; Type II diabetes; Zucker diabetic fatty

Indexed keywords

FRUCTOSAMINE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LIRAGLUTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; FEEDING; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HISTOLOGY; INNER CELL MASS; INSULIN BLOOD LEVEL; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PANCREAS RESECTION; PRIORITY JOURNAL; RAT; RAT STRAIN; TREATMENT FAILURE;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; INSULIN; ISLETS OF LANGERHANS; MALE; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER;

EID: 10744230106     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705397     Document Type: Article

References (52)

1. AGERSØ, H., JENSEN, L.B., ELBRØND, B., ROLAN, P. & ZDRAVKOVIC, M. (2002). The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia, 45, 195-202.
2. BOCK, T., SVENSTRUP, K., PAKKENBERG, B. & BUSCHARD, K. (1999). Unbiased estimation of total beta-cell number and mean beta-cell volume in rodent pancreas. APMIS, 107, 791-799.
3. BREGENHOLT, S., MOLDRUP, A., KNUDSEN, L.B. & PETERSEN, J.S. (2001). The GLP-1 derivative NN2211 inhibits cytokine-induced apoptosis in primary rat β-cells. Diabetes, 50 (Suppl 2), A31.
4. BURCELIN, R., DA COSTA, A., DRUCKER, D. & THORENS, B. (2001). Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes, 50, 1720-1728.
5. BUTEAU, J., RODUIT, R., SUSINI, S. & PRENTKI, M. (1999). Glp-1 promotes DNA synthesis, activates phosphatidylinositol-3-kinase and increases transcription factor pancreatic and duodenal home-box gene 1 (PDX-1) DNA binding activity in beta (INS-1) cells. Diabetologia, 42, 856-864.
6. CLARK, J.B., PALMER, C.J. & SHAW, W.N. (1983). The diabetic Zucker Fatty rat. Proc. Soc. Exp. Biol. Med., 173, 68-75.
7. D'ALESSIO, D.A., FUJIMOTO, W.Y. & ENSINCK, J.W. (1989). Effects of glucacon-like peptide I-(7-36) on release of insulin, glucagon, and somatostatin by rat pancreatic islet cell monolayer cultures. Diabetes, 38, 1534-1538.
8. DEACON, C.F., JOHNSEN, A.H. & HOLST, J.J. (1995). Degradation of glucagons-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab., 80, 952-957.
9. DEACON, C.F., PRIMDAL, L., KLARSKOV, L., OLESEN, M. & HOLST, J.J. (1996). Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in anesthetized pig. Am. J. Physiol., 271, E458-E464.
10. EDVELL, A. & LINDSTRÖM, P. (1999). Initiation of increased pancreatic islet growth in young normoglycaemic mice (Umeå +/?). Endocrinology, 140, 778-783.
11. ETGEN, G.J. & OLDHAM, B.A. (2000). Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state. Metabolism, 49, 684-688.
12. FARILLA, L., HUI, H., BERTOLOTTO, C., KANG, E., BULOTTA, A., DI MARIO, U. & PERFETTI, R. (2002). Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology, 143, 4397-4408.
13. FLINT, A., RABEN, A., ASTRUP, A. & HOLST, J.J. (1998). GLP-1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest., 101, 515-520.
14. FRIEDMAN, J.E., DE VENTE, J.E., PETERSON, R.G. & DOHM, G.L. (1991). Altered expression of muscle glucose transporter GLUT-4 in diabetic fatty Zucker rats (ZDF/Drt-fa). Am. J. Physiol., 261, E782-E788.
15. GREIG, N.H., HOLLOWAY, H.N., DEORE, K.A., JANI, D., WANG, Y., ZHOU, J., GARANT, M.J. & EGAN, J.M. (1999). Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia, 42, 45-50.
16. GRIFFEN, S.C., WANG, J. & GERMAN, M.S. (2001). A genetic defect in β-cell gene expression segregates independently from the fa locus in the ZDF rat. Diabetes, 50, 63-68.
17. GROMADA, J., HOLST, J.J. & RORSMAN, P. (1998). Cellular regulation of islet hormone secretion by the incretin hormone GLP-1. Pflugers Arch. Eur. J. Phys., 435, 583-594.
18. GUTNIAK, M.K., LINDE, B., HOLST, J.J. & EFENDIC, S. (1994). Subcutaneous injection of the incretin hormone GLP-1 abolishes postprandial glycemia in NIDDM. Diabetes Care, 17, 1039-1044.
19. HOLST, J.J. (1997). Enteroglucagon. Annu. Rev. Physiol., 59, 257-271.
20. JOHANSEN, I., DECKERT, M., MANDRUP-POULSEN, T. & MALMLÖF, K. (1999). The role of growth hormone and glucocorticoid in glucose handling in vivo. J. Endocrinol., 162, 87-93.
21. JUHL, C.B., HOLLINGDAL, M., PORKSEN, N., STURIS, J., JAKOBSEN, G. & SCHMITZ, O. (2002). Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in Type 2 diabetes. Diabetes, 51, 484-492.
22. KNUDSEN, L.B., NIELSEN, P.F., HUUSFELDT, P.O., JOHANSEN, N.L., MADSEN, K., PEDERSEN, F.Z., THØGERSEN, H., WILKEN, M. & AGERSØ, H. (2000). Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem., 43, 1664-1669.
23. KREYMANN, B., GHATEI, M.A., WILLIAMS, G. & BLOOM, S.R. (1987). Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet, II, 1300-1303.
24. LARSEN, J., HYLLEBERG, G., NG, K. & DAMSBO, P. (2001a). Glucagon-like peptide-1 infusion must be maintained for 24h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care, 24, 1416-1421.
25. LARSEN, P.J., FLEDELIUS, C., KNUDSEN, L.B. & TANG-CHRISTENSEN, M. (2001b). Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes, 50, 2530-2539.
26. LI, Y., HANSOTIA, T., YUSTA, B., RIS, F., HALBAN, P.A. & DRUCKER, D.J. (2003). Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem., 278, 471-478.
27. LIU, Y.Q., NEVIN, P.W. & LEAHY, J.L. (2000). Beta-cell adaptation in 60% pancreatectomy rats that preserves normoinsulinemia and normoglycemia. Am. J. Physiol., 278, E68-E73.
28. MACDONALD, P.E., EL-KHOLY, W., RIEDEL, M.J., SALAPATEK, A.M.F., LIGHT, P.E. & WHEELER, M.B. (2002). The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes, 51 (Suppl 3), S434-S442.
29. MENTLEIN, R., GALLWITZ, B. & SCHMIDT, W.E. (1993). Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagons-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem., 214, 829-835.
30. MOLDRUP, A., GRAM, V.K., FRIEDRICHSEN, B.N., NIELSEN, J.H. & PETERSEN, J.S. (2001). Glucagon-like peptide-1 (GLP-1) and the long-acting GLP-1 derivative, NN2211, stimulate expansion of primary rat beta-cells in a camp/protein kinase A (PKA)-dependent manner. Diabetes, 50 (Suppl 2), A336.
31. MOVASSAT, J., BEATTIE, G.M., LOPEZ, A.D. & HAYEK, A. (2002). Exendin 4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells. J. Clin. Endocrinol. Metab., 87, 4775-4781.
32. NAUCK, M.A., KLEINE, N., ORSKOV, C., HOLST, J.J., WILLMS, B. & CREUTZFELDT, W. (1993). Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia, 36, 741-744.
33. NAUCK, M.A., NIEDEREREICHHOLZ, U., ETTLER, R., HOLST, J.J., ØRSKOV, C., RITZEL, R. & SCHMIGEL, W.H. (1997). Glucagon-like peptide-1 inhibition of gastric-emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol., 273, E981-E988.
34. OHNEDA, M., INMAN, L.R. & UNGER, R.H. (1995). Caloric restriction in obese pre-diabetic rats prevents beta-cell depletion, loss of beta-cell GLUT 2 and glucose incompetence. Diabetologia, 38, 173-179.
35. ØRSKOV, C. (1992). Glucagon-like peptide-1, a new hormone of the enteroinsular axis. Diabetologia, 35, 701-711.
36. PERFETTI, R., ZHOU, J., DOYLE, M.E. & EGAN, J.M. (2000). Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology, 141, 4600-4605.
37. PHILLIPS, M.S., LIU, Q., HAMMOND, H.A., DUGAN, V., HEY, P.J., CASKEY, C.J. & HESS, J.F. (1996). Leptin receptor missense mutation in the fatty Zucker rat. Nat. Genet., 13, 18-19.
38. RACHMAN, J., BARROW, B.A., LEVY, J.C. & TURNER, R.C. (1997). Near normalization of diurnal glucose concentrations by continuous administration of GLP-1 in subjects with NIDDM. Diabetologia, 40, 205-211.
39. RIBEL, U., LARSEN, M.O., ROLIN, B., CARR, R.D., WILKEN, M., STURIS, J., WESTERGAARD, L., DEACON, C.F. & KNUDSEN, L.B. (2002). NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs, Eur. J. Pharmacol., 451, 217-225.
40. ROLIN, B., LARSEN, M.O., GOTFREDSEN, C.F., DEACON, C.F., CARR, R.D., WILKEN, M. & KNUDSEN, L.B. (2002). The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice. Am. J. Physiol. Endocrinol. Metab., 283, E745-E752.
41. SREENAN, S., STURIS, J., PUGH, W.L., BURANT, C.F. & POLONSKY, K.S. (1996). Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. Am. J. Physiol., 271, E742-E747.
42. STARK, A. & MENTLEIN, R. (2002). Somatostatin inhibits glucagon-like peptide-1-induced insulin secretion and proliferation of RINm5F insulinoma cells. Regul. Pept., 108, 97-102.
43. STURIS, J., PUGH, W.L., TANG, J. & POLONSKY, K.S. (1995). Prevention of diabetes does not completely prevent insulin secretory defects in the ZDF Rat. Am. J. Physiol., 269, E786-E792.
44. SZAYNA, M., DOYLE, M.E., BETKEY, J.A., HOLLOWAY, H.W., SPENCER, R.G., GREIG, N.H. & EGAN, J.M. (2000). Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology, 141, 1936-1941.
45. TOFT-NIELSEN, M.B., MADSBAD, S. & HOLST, J.J. (1999). Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care, 22, 1137-1143.
46. TOLESSA, T., GUTNIAK, M., HOLST, J.J., EFENDIC, S. & HELLSTRÖM, P.M. (1998). Inhibitory effect of glucagon-like peptide-1 on small bowel motility. J. Clin. Invest., 102, 764-774.
47. VELLA, A., SHAH, P., BASU, R., BASU, A., HOLST, J.J. & RIZZA, R.A. (2000). Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes, 49, 611-617.
48. WETTERGREN, A., SCHJOLDAGER, B., MORTENSEN, P.E., MYHRE, J., CHRISTIANSEN, J. & HOLST, J.J. (1993). Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig. Dis. Sci., 38, 665-673.
49. WILKEN, M., LARSEN, F.S., JUUL, A.-G., JENSEN, L.B. & RIBEL, U. (2000). An immunoassay for the GLP-1 derivative NN2211. Diabetologia, 43 (Suppl. 1), A148.
50. WILLMS, B., WERNER, J., HOLST, J.J., ØRSKOV, C., CREUTZFELDT, W. & NAUCK, M. (1996). Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous GLP-1 (7-36)amide in type 2 (noninsulin-dependent) diabetic patients. J. Clin. Endocrinol. Metab., 81, 327-332.
51. XU, G., STOFFERS, D.A., HABENER, J.F. & BONNER-WEIR, S. (1999). Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes, 48, 2270-2276.
52. ZANDER, M., MADSBAD, S. & HOLST, J.J. (2002). GLP-1 treatment for 6 weeks improves glycaemic control, insulin sensitivity and β-cell function in type 2 diabetic patients. Lancet, 359, 824-830.